RARE News and Press, Ultragenyx Pharmaceutical Inc. From 07/28/22

Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q2 GAAP EPS of -$2.26 misses by $0.49 . Revenue of $89.34M (+2.7% Y/Y) beats by $2.01M . As of June 30, 2022, cash, cash equivalents, and marketable debt securities were $706.1 million Outlook: T...

Second quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories 1 of $64.0 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 millio...

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close. The consensus EPS Estimate is -$1.64 and the consensus Revenue Estimate is $87.33M (+0.4% Y/Y). Over the last 3 months, EPS estimates hav...

NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ca...

With earnings season beginning to pick up steam, Wall Street experienced a buying spree on Tuesday. The Nasdaq led the broad-based advance, climbing 3% as the major averages bounced back from recent weakness. Amid the overall gains, Apellis ( APLS ) represented a standout performer....

Investors don't appear happy with Ultragenyx Pharmaceutical's ( NASDAQ: RARE ) closing bell announcement Monday that it would be acquiring GeneTx Biotherapeutics , which is solely focused on its Angelman syndrome drug GTX-102. Volume in Ultragenyx is much higher than n...

Gainers: Sidus Space ( SIDU ) +34% . DermTech ( DMTK ) +25% . Eos Energy Enterprises ( EOSE ) +24% . NuCana ( NCNA ) +21% . Power REIT ( PW ) +21% . Apellis Pharmaceuticals ( APLS ) +20% . Silvergate ( SI ) ...

Shares of the rare disease specialist Ultragenyx Pharmaceutical (NASDAQ: RARE) are having a rough session Tuesday. Specifically, the biotech's stock dropped by as much as 17% in early morning action. The company's shares have rebounded to some degree since, but Ultragenyx's ...

Gainers: Apellis Pharmaceuticals APLS +22% . Neuronetics STIM +17% . Nyxoah ( NYXH ) +17% . Celyad Oncology ( CYAD ) +8% . NuCana ( NCNA ) +7% . Losers: High Tide HITI -21% . Ultragenyx Pharmaceutical ( RARE ...

Ultragenyx Pharmaceutical ( NASDAQ: RARE ) on Monday said it had exercised its option to acquire GeneTx Biotherapeutics for a $75M upfront payment following promising interim data from a phase 1/2 study of the privately-held biotech company's investigational drug GTX-102. ...